Safety and immunologic non-inferiority of 13-valent pneumococcal conjugate vaccine given
as a 3-dose series with routine vaccines in healty children/Esposito, S.; Tansey, S.; …

Background Pneumococcal diseases among children aged< 5 years worldwide are
associated with high annual mortality rates. Purpose This study aimed to evaluate the …

Background: Pneumococcal disease remains a public health priority worldwide. This phase
2 study (V114-008; NCT02987972; EudraCT 2016-001117-25) compared safety and …

Pneumococcal infections are a major cause of morbidity and mortality worldwide.
Pneumococcal conjugate vaccines represent major progress in the prevention of invasive …

Background: Global pediatric immunization programs with pneumococcal conjugate
vaccines (PCVs) have reduced vaccine-type pneumococcal disease, but a substantial …

Background: The global distribution of pneumococcal disease and emergence of
nonvaccine pneumococcal serotypes prompted the development of a 13-valent …

Importance Immunization schedules with pneumococcal conjugate vaccine (PCV) differ
among countries regarding the number of doses, age at vaccinations, and interval between …

Introduction The invasive pneumococcal diseases (IPDs) caused by Streptococcus
pneumoniae pose an enormous threat to children under 5 years of age. However, routine …

Background The 13-valent pneumococcal conjugate vaccine (PCV13) was licensed based
on the results of immunogenicity studies and correlates of protection derived from …

13-valent pneumococcal conjugate vaccine (PCV13) was compared to PCV7 in infants
administered 4 doses. For the 7 common serotypes, PCV13-and PCV7-elicited responses …